Use of new oral anticoagulants in antiphospholipid syndrome.

@article{Arachchillage2013UseON,
  title={Use of new oral anticoagulants in antiphospholipid syndrome.},
  author={Deepa Ranjani Jayakody Arachchillage and Hannah Cohen},
  journal={Current rheumatology reports},
  year={2013},
  volume={15 6},
  pages={331}
}
The current mainstay of treatment of thrombotic APS is long-term anticoagulation with oral vitamin K antagonists (VKA) such as warfarin. However, the use of warfarin is problematic, particularly in patients with antiphospholipid syndrome (APS). The new oral anticoagulants (NOAC) include dabigatran etexilate (Pradaxa®), a direct thrombin inhibitor, and rivaroxaban (Xarelto®), Apixaban (Eliquis) and Edoxaban (Lixiana®), which are direct anti-Xa inhibitors. Unlike warfarin, these agents do not… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Similar Papers

Loading similar papers…